Published in Drug Week, February 11th, 2005
Rambazole is a novel retinoic acid metabolism-blocking agent (RAMBA). A review of initial phase IIa trial data from 10 patients with moderate to severe psoriasis demonstrated a reduction in the PASI score (a symptom severity score in psoriatic patients) by an average of 50% in patients treated with 1mg once daily for 8 consecutive weeks.
These PASI scores were measured at week 10, 2...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.